Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:GMAB NASDAQ:PTCT NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$196.13-0.8%$184.93$114.53▼$208.16$12.00B0.39487,191 shs166,620 shsGMABGenmab A/S$27.87-2.6%$23.41$17.24▼$28.75$17.88B0.931.44 million shs1.01 million shsPTCTPTC Therapeutics$60.83-0.2%$50.03$33.19▼$62.18$4.85B0.531.10 million shs1.24 million shsSMMTSummit Therapeutics$18.93+1.8%$25.55$15.55▼$36.91$14.06B-1.023.77 million shs5.35 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.40%-0.23%+0.86%+15.73%+75.04%GMABGenmab A/S+3.17%+4.49%+30.82%+25.37%+6.24%PTCTPTC Therapeutics+4.51%+5.09%+34.66%+18.92%+88.91%SMMTSummit Therapeutics+5.68%-21.85%-27.57%-5.97%-18.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$196.13-0.8%$184.93$114.53▼$208.16$12.00B0.39487,191 shs166,620 shsGMABGenmab A/S$27.87-2.6%$23.41$17.24▼$28.75$17.88B0.931.44 million shs1.01 million shsPTCTPTC Therapeutics$60.83-0.2%$50.03$33.19▼$62.18$4.85B0.531.10 million shs1.24 million shsSMMTSummit Therapeutics$18.93+1.8%$25.55$15.55▼$36.91$14.06B-1.023.77 million shs5.35 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.40%-0.23%+0.86%+15.73%+75.04%GMABGenmab A/S+3.17%+4.49%+30.82%+25.37%+6.24%PTCTPTC Therapeutics+4.51%+5.09%+34.66%+18.92%+88.91%SMMTSummit Therapeutics+5.68%-21.85%-27.57%-5.97%-18.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$244.3624.59% UpsideGMABGenmab A/S 2.70Moderate Buy$39.2540.83% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.0013.43% UpsideSMMTSummit Therapeutics 2.65Moderate Buy$33.7978.44% UpsideCurrent Analyst Ratings BreakdownLatest PTCT, GMAB, SMMT, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.009/2/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/27/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $50.008/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $71.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$490.75M24.46N/AN/A($1.88) per share-104.33GMABGenmab A/S$3.12B5.73$1.52 per share18.29$8.04 per share3.47PTCTPTC Therapeutics$1.76B2.74N/AN/A($14.24) per share-4.27SMMTSummit TherapeuticsN/AN/AN/AN/A$0.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A817.22N/A-54.94%N/A-24.31%11/13/2025 (Estimated)GMABGenmab A/S$1.14B$1.9914.0115.661.6237.53%21.03%16.98%11/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.978.76N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest PTCT, GMAB, SMMT, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69GMABGenmab A/SN/A6.226.20PTCTPTC TherapeuticsN/A3.623.57SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AGMABGenmab A/S7.07%PTCTPTC TherapeuticsN/ASMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%GMABGenmab A/S1.54%PTCTPTC Therapeutics5.50%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableGMABGenmab A/S2,682641.59 million631.71 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionablePTCT, GMAB, SMMT, and ASND HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?2 hours ago | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12 at 8:02 AM | insidertrades.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 12 at 2:19 AM | americanbankingnews.comSummit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval QuestionsSeptember 10 at 5:27 PM | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 10 at 3:03 PM | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedSeptember 10 at 1:54 PM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 10 at 9:59 AM | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at HC WainwrightSeptember 10 at 8:51 AM | marketbeat.comCORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 9 at 12:43 AM | globenewswire.comSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.September 9 at 3:35 PM | globenewswire.comSMMT Stock Plummets 25% on Regional Data Differences in NSCLC StudySeptember 9 at 2:21 PM | zacks.comPolar Asset Management Partners Inc. Trims Holdings in Summit Therapeutics PLC $SMMTSeptember 9 at 5:21 AM | marketbeat.com538,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Adage Capital Partners GP L.L.C.September 9 at 4:15 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Given Overweight Rating at Cantor FitzgeraldSeptember 9 at 2:57 AM | americanbankingnews.comSummit Therapeutics falls -24.1%September 8, 2025 | msn.comSummit Therapeutics (SMMT) WCLC Update Call (Transcript)September 8, 2025 | seekingalpha.comSummit Therapeutics (SMMT) WCLC Update CallSeptember 8, 2025 | seekingalpha.comSummit Therapeutics shares fall as lung cancer trial results disappointSeptember 8, 2025 | proactiveinvestors.comIvonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332September 7, 2025 | prnewswire.comLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in ...September 7, 2025 | finance.yahoo.comVident Advisory LLC Acquires Shares of 41,183 Summit Therapeutics PLC $SMMTSeptember 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTCT, GMAB, SMMT, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$196.13 -1.54 (-0.78%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Genmab A/S NASDAQ:GMAB$27.87 -0.74 (-2.58%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.PTC Therapeutics NASDAQ:PTCT$60.83 -0.13 (-0.22%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Summit Therapeutics NASDAQ:SMMT$18.93 +0.33 (+1.80%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
